Trial Profile
Phase II study of RAD001 in a neoadjuvant setting in men with intermediate or high risk prostate cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 19 Jan 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 May 2008 New trial record.